ACTS-GC

NCT00152217 📎

Regimen

Experimental
adjuvant S-1 for 1 year
Control
surgery only

Population

Japanese patients with stage II/III gastric cancer after curative D2 gastrectomy

Key finding

3y OS 80.1% vs 70.1% (HR for death 0.68, 95% CI 0.52-0.87, P=0.003); 5y OS 71.7% vs 61.1% in long-term f/u (HR 0.669)

Source: PMID 17978289

Timeline

    Guideline citations

    • CSCO GASTRIC 2025 (p.65)⚠️ OCR source